Incannex Healthcare Inc. IXHL PHARMA
Company Overview
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Why Investors Should Care
Revenue has grown at a 616.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Jun 2025 Revenue of $86.00K (+616.7% YoY); net profit $-46.88M.
- Trailing 12 Months Year-on-year growth — revenue +616.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 616.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 616.67% |
| 1 Year: | 616.67% |
Stock Price Performance
| 1 Year: | -71.92% |
| 6 Months: | -20.33% |
| 3 Months: | -0.88% |
| 1 Month: | +6.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)50.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 616.7% over 5 years.
CONS
- Trading 84.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IXHL Incannex Healthcare Inc. PHARMA | 3.37 | -0.20 | $40.32M | 0.00% | - | -117.17% | 616.67% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 74.00K | 12.00K | - | - | - | - |
| Operating Income | -3.64M | -3.65M | -4.89M | -7.98M | -7.42M | -6.25M | -5.00M | -5.00M | -6.79M | -7.00M | -4.05M |
| Net Income | -2.92M | -3.57M | -726.00K | -5.24M | -6.03M | -5.42M | -5.89M | -3.97M | -6.41M | -6.52M | -3.88M |
| Diluted EPS | 0.05 | -0.22 | -0.08 | -0.33 | -0.38 | -0.29 | -0.33 | -6.19 | -0.02 | -0.02 | -0.35 |
| R&D Expense | 1.55M | 1.64M | 2.61M | 2.64M | 3.28M | 2.90M | 1.41M | 2.73M | 1.12M | 2.28M | 321.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Revenue | - | 12.00K | 86.00K |
| Operating Income | -49.67M | -30.04M | -23.79M |
| Net Income | -48.81M | -18.46M | -46.88M |
| Diluted EPS | -3.32 | -1.15 | -1.35 |
| R&D Expense | 6.31M | 12.88M | 10.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | - | 23.78M | 17.05M | 20.45M |
| Total Equity | 24.71M | 20.82M | 11.22M | 13.39M |
| Cash & Equivalents | - | 22.12M | 5.86M | 15.04M |
| Total Liabilities | - | 2.96M | 5.83M | 7.06M |
| Current Liabilities | - | 2.55M | 5.62M | 6.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Operating Cash Flow | -10.75M | -15.85M | -12.51M |
| Investing Cash Flow | -316.00K | -277.00K | -8.00K |
| Financing Cash Flow | 8.18M | - | 21.40M |
| Capital Expenditure | -316.00K | -277.00K | -8.00K |
| Free Cash Flow | -11.06M | -16.12M | -12.52M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | -250,341.7% | -27,661.6% |
| Net Margin % | - | -153,825.0% | -54,517.4% |
| ROE % | -234.4% | -164.6% | -350.2% |
| ROCE % | -233.9% | -262.9% | -176.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | LPL Financial LLC | 1.24% | 148.18K | $539.37K |
| 2 | Millennium Management Llc | 0.80% | 95.25K | $346.72K |
| 3 | Jane Street Group, LLC | 0.65% | 78.19K | $284.63K |
| 4 | AdvisorShares Investments, LLC | 0.51% | 60.87K | $221.56K |
| 5 | Susquehanna International Group, LLP | 0.24% | 28.77K | $104.73K |
| 6 | Commonwealth Equity Services, LLC | 0.12% | 14.03K | $51.06K |
| 7 | Citadel Advisors Llc | 0.09% | 10.35K | $37.67K |
| 8 | Osaic Holdings Inc. | 0.05% | 6.38K | $23.21K |
| 9 | UBS Group AG | 0.03% | 3.61K | $13.14K |
| 10 | Morgan Stanley | 0.03% | 3.56K | $12.95K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IXHL
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designationNEW YORK and MELBOURNE, Australia, Aug. 25,…
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
Completion of more than A$11.2 million in non-dilutive capital received under the Australian Government’s R&D Tax Incentive Program further strengthens Company’s balance sheet and financial flexibilityNEW YORK and MELBOURNE, Australia, Aug.…
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
First clinical sites approved and actively screening potential participantsRepresents another major milestone in the advancement of IHL-42X towards Phase III developmentIHL-42X has received FDA Fast Track designation, highlighting its poten…
Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X
Incannex Healthcare Inc. (NASDAQ:IXHL) is one of the best strong buy penny stocks to invest in now. Incannex Healthcare Inc. (NASDAQ:IXHL) announced on June 25 the granting of a key patent by the United States Patent and Trademark Office (U…
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impa…
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 mi…
IXHL — Frequently Asked Questions
What is the current share price of Incannex Healthcare Inc. (IXHL)?
As of 2026-09-19 21:16 PDT, Incannex Healthcare Inc. (IXHL) trades at $3.37 on NasdaqCM. Its 52-week range is $2.56 to $22.23.
What is the market capitalisation of IXHL?
Incannex Healthcare Inc. (IXHL) has a market capitalisation of $40.32M on NasdaqCM.
What is the P/E ratio of IXHL?
IXHL trades at a trailing price-to-earnings (P/E) ratio of -0.20. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.66.
What is the return on equity (ROE) of IXHL?
IXHL has a return on equity (ROE) of -117.17%.
Is IXHL a good stock to buy?
This page provides a data-driven analysis of Incannex Healthcare Inc. (IXHL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.